Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has a collaboration agreement with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:QTRX
CUSIPN/A
Phone617-301-9400
Debt
Debt-to-Equity RatioN/A
Current Ratio3.36
Quick Ratio3.13
Price-To-Earnings
Trailing P/E Ratio-1.90
Forward P/E Ratio-14.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.87 million
Price / Sales15.13
Cash FlowN/A
Price / CashN/A
Book Value$3.02 per share
Price / Book5.22
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees126
Outstanding Shares21,960,000
Quanterix (NASDAQ:QTRX) Frequently Asked Questions
What is Quanterix's stock symbol?
Quanterix trades on the NASDAQ under the ticker symbol "QTRX."
How were Quanterix's earnings last quarter?
Quanterix Corp (NASDAQ:QTRX) posted its earnings results on Wednesday, May, 9th. The company reported ($0.33) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.08. View Quanterix's Earnings History.
When is Quanterix's next earnings date?
What price target have analysts set for QTRX?
4 Wall Street analysts have issued 12 month target prices for Quanterix's shares. Their forecasts range from $26.00 to $27.00. On average, they anticipate Quanterix's share price to reach $26.50 in the next twelve months. View Analyst Ratings for Quanterix.
What are Wall Street analysts saying about Quanterix stock?
Here are some recent quotes from research analysts about Quanterix stock:
- 1. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (6/20/2018)
- 2. BTIG Research analysts commented, "Acceleration, and Expanding NT PT:1Q18 revenue growth of +41% exceeded consensus of +33% driven by strength in higher margin consumable and service revenue growth. Pharma/Biotech/CRO segment (46% of revenue) grew +48%, and Academic (46% of revenue) grew +33%. Academic should continue to strengthen with the recent launch of SR-X (1Q represented first full quarter of commercial sales; Asia launch on target for 2Q). While formal guidance for the full year remains unavailable, management is committed to delivering consensus expectations (~50% revenue growth). Looking ahead, QTRX expects to increase its sales force emphasis on the Accelerator business NT leveraging its recently acquired CLIA lab facilities (Aushon tuck-in), and in order to capitalize on the recent regulatory developments increasingly focusing on biomarker incorporation throughout biopharma preclinical/clinical trials." (5/13/2018)
Who are some of Quanterix's key competitors?
Some companies that are related to Quanterix include Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), Eyepoint Pharmaceuticals (EYPT), HTG Molecular Diagnostics (HTGM), Arrayit Corp common stock (ARYC), Aethlon Medical (AEMD), Precipio (PRPO), Pressure Biosciences (PBIO), Scientific Industries (SCND) and PositiveID (PSID).
Who are Quanterix's key executives?
Quanterix's management team includes the folowing people:
- Mr. E. Kevin Hrusovsky, Exec. Chairman, Pres & CEO (Age 57)
- Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 65)
- Mr. Bruce J. Bal, VP of Operations, Service & Quality (Age 59)
- Dr. Mark T. Roskey Ph.D., Sr. VP & GM of Applications & Reagents (Age 58)
- Mr. Joseph S. Driscoll, Chief Financial Officer (Age 53)
When did Quanterix IPO?
(QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.
When did the company's lock-up period expire?
Quanterix's lock-up period expired on Tuesday, June 5th. Quanterix had issued 4,275,200 shares in its initial public offering on December 7th. The total size of the offering was $64,128,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.
Has Quanterix been receiving favorable news coverage?
News headlines about QTRX stock have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quanterix earned a media sentiment score of 0.13 on Accern's scale. They also assigned news articles about the company an impact score of 47.24 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Quanterix's major shareholders?
Quanterix's stock is owned by a number of of institutional and retail investors. Top institutional investors include Park West Asset Management LLC (0.95%), BlackRock Inc. (0.92%), Millennium Management LLC (0.73%), Opaleye Management Inc. (0.68%), Northern Trust Corp (0.24%) and Citadel Advisors LLC (0.12%). Company insiders that own Quanterix stock include David R Walt, E Kevin Hrusovsky, Ernest Orticerio and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix.
Which institutional investors are selling Quanterix stock?
Which institutional investors are buying Quanterix stock?
QTRX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Opaleye Management Inc., Northern Trust Corp, Citadel Advisors LLC, Schwab Charles Investment Management Inc. and California State Teachers Retirement System. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix.
How do I buy shares of Quanterix?
Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Quanterix's stock price today?
One share of QTRX stock can currently be purchased for approximately $15.76.
How big of a company is Quanterix?
Quanterix has a market capitalization of $348.95 million and generates $22.87 million in revenue each year. The company earns $-27,010,000.00 in net income (profit) each year or ($8.30) on an earnings per share basis. Quanterix employs 126 workers across the globe.
How can I contact Quanterix?
Quanterix's mailing address is 113 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-301-9400.
MarketBeat Community Rating for Quanterix (QTRX)
MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
